PetMed Express Q1 2027 earnings miss sends shares lower

PetMed Express Inc. reported first-quarter 2027 earnings that fell short of analyst expectations, sending its shares down in extended trading on Wednesday.

The veterinary pharmaceutical and pet-care products distributor posted adjusted earnings per share of $0.22, missing the consensus estimate of $0.28, according to Refinitiv data. Revenue totaled $185.3 million, below the $192.4 million forecast.

Management attributed the shortfall to softer demand for its core products and higher operational expenses, including supply chain and labor costs. The company also noted that inflationary pressures had weighed on discretionary pet spending, a key driver of its revenue.

Chief Executive Officer Matt Hulett said in a statement that while the company remains focused on cost discipline, near-term headwinds from economic uncertainty and competitive pricing are expected to persist. PetMed Express maintained its full-year 2027 guidance, though analysts questioned the outlook’s feasibility given the first-quarter miss.

Shares of PetMed Express fell 5.2% in after-hours trading following the release, extending losses from the prior session. The stock has declined 8.7% over the past month, underperforming the broader health-care sector.

Analysts at Jefferies downgraded the stock to Hold from Buy, citing the earnings miss and margin compression. The firm also trimmed its price target to $22 from $25, reflecting reduced visibility on near-term profitability.

PetMed Express has faced challenges in recent quarters, including declining pet adoption rates and increased competition from e-commerce platforms. The company’s reliance on discretionary pet care spending has made it particularly sensitive to macroeconomic downturns.